ERBB2 and non-small cell lung carcinoma: In HER2-positive and HER2-low breast cancers, HER-positive gastric or gastroesophageal junction cancers and HER2-mutant non-small-cell lung cancer, T-DXd has become a Food and Drug Administration (FDA)-approved standard of care.